Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
2 Articles
2 Articles
Daily oral GLP-1 medication linked to similar weight loss across three menopausal stages
New analyses to be presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, show that orforglipron, a daily oral medication for weight loss and type 2 diabetes, was associated with similar weight loss among women of different ages and at different life stages: before, during and after menopause.
Endocrinology mariasanchezmonge European Congress of Diabetes Orforglipron, oral GLP-1 approved by the FDA and in evaluation by the European Medicines Agency (EMA), achieves a similar weight loss in women of different ages and stages of life: premenopause, perimenopause and postmenopause. This is demonstrated by the new analyses that will be presented at the Annual Congress of the European Association for the Study of Diabetes (EASD), to be held…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
